Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.37 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.33 |
| ▸ | ACHE | P22303 | 3/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20170728 | 1.00 | OPRM1 (0.37) | OPRM1NQO2MTNR1AMTNR1BHCRTR1 | |
| SCHEMBL20170607 | 1.00 | OPRM1 (0.37) | OPRM1NQO2MTNR1AMTNR1BHCRTR1 | |
| SCHEMBL20170605 | 0.85 | ADRA1A (0.35) | — | |
| SCHEMBL20170612 | 0.85 | ADRA1A (0.35) | — | |
| SCHEMBL20170753 | 0.82 | GABRA1 (0.39) | NQO2MTNR1AMTNR1BHCRTR1 | |
| SCHEMBL20170868 | 0.81 | — | — | |
| SCHEMBL20170592 | 0.80 | MTNR1A (0.40) | NQO2MTNR1AMTNR1BHCRTR1 | |
| SCHEMBL20170738 | 0.79 | HTR1A (0.40) | NQO2MTNR1AMTNR1BHCRTR1 | |
| SCHEMBL20170641 | 0.76 | ADRA1A (0.34) | OPRM1NQO2MTNR1AMTNR1B | |
| SCHEMBL20170669 | 0.76 | ADRA1A (0.34) | OPRM1NQO2MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593095-B1 | (+)-MORPHINANS AS ANTAGONISTS OF TOLL-LIKE RECEPTOR 9 AND THERAPEUTIC USES THEREOF | MALLINCKRODT LLC (US) | 2019-03-27 | — | — | EP | disclosed |
| EP-2453895-B1 | (+) - MORPHINANS AS ANTAGONISTS OF TOLL-LIKE RECEPTOR 9 AND THERAPEUTIC USES THEREOF | MALLINCKRODT LLC (US) | 2018-05-23 | — | — | EP | disclosed |